Figure 5.

Extending α-BAFF treatment improves the re-administration efficacy

(A) Longitudinal quantification of plasma BAFF levels for control (no-IS) and various IS treatment groups (n = 5–10/group). (B) Schematic representation for timing and dosing of α-CD20 and extended α-BAFF treatments and AAV8. AAV8 capsid-specific IgM (C) and IgG2c (D) Ab levels in plasma samples collected at different time points post primary and -secondary AAV8 administration. (E) Circulating hFIX levels at 4 weeks post-re-administration with AAV8-hFIX. Statistical significance was calculated by one-way ANOVA (Dunnett’s multiple comparisons) for (E), and two-way ANOVA for (A), (C), and (D). ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.